» Articles » PMID: 38090385

Machine-learning Radiomics to Predict Bone Marrow Metastasis of Neuroblastoma Using Magnetic Resonance Imaging

Overview
Journal Cancer Innov
Date 2023 Dec 13
PMID 38090385
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroblastoma is one common pediatric malignancy notorious for high temporal and spatial heterogeneities. More than half of its patients develop distant metastases involving vascularized organs, especially the bone marrow. It is thus necessary to have an economical, noninvasive method without much radiation for follow-ups. Radiomics has been used in many cancers to assist accurate diagnosis but not yet in bone marrow metastasis in neuroblastoma.

Methods: A total of 182 patients with neuroblastoma were retrospectively collected and randomly divided into the training and validation sets. Five-hundred and seventy-two radiomics features were extracted from magnetic resonance imaging, among which 41 significant ones were selected via -test for model development. We attempted 13 machine-learning algorithms and eventually chose three best-performed models. The integrative performance evaluations are based on the area under the curves (AUCs), calibration curves, risk deciles plots, and other indexes.

Results: Extreme gradient boosting, random forest (RF), and adaptive boosting were the top three to predict bone marrow metastases in neuroblastoma while RF was the most accurate one. Its AUC was 0.90 (0.86-0.93), F1 score was 0.82, sensitivity was 0.76, and negative predictive value was 0.79 in the training set. The values were 0.82 (0.71-0.93), 0.80, 0.75, and 0.92 in the validation set, respectively.

Conclusions: Radiomics models are likely to contribute more to metastatic diagnoses and the formulation of personalized healthcare strategies in clinics. It has great potential of being a revolutionary method to replace traditional interventions in the future.

Citing Articles

Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.

Lozano-Montoya J, Jimenez-Pastor A, Fuster-Matanzo A, Weiss G, Cerda-Alberich L, Veiga-Canuto D Front Oncol. 2025; 15:1528836.

PMID: 40061893 PMC: 11886962. DOI: 10.3389/fonc.2025.1528836.


Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning.

Pan S, Wang Z Front Immunol. 2025; 15:1516524.

PMID: 39931579 PMC: 11807960. DOI: 10.3389/fimmu.2024.1516524.


Pan-cancer secreted proteome and skeletal muscle regulation: insight from a proteogenomic data-driven knowledge base.

Parry T, Gilmore L, Khamoui A Funct Integr Genomics. 2025; 25(1):14.

PMID: 39812750 DOI: 10.1007/s10142-024-01524-7.


Predicting Bone Marrow Metastasis in Neuroblastoma: An Explainable Machine Learning Approach Using Contrast-Enhanced Computed Tomography Radiomics Features.

Wang H, He L, Chen X, Ding S, Xie M, Cai J Technol Cancer Res Treat. 2024; 23:15330338241290386.

PMID: 39440370 PMC: 11500234. DOI: 10.1177/15330338241290386.


Radiomics models to predict bone marrow metastasis of neuroblastoma using CT.

Chen X, Chen Q, Liu Y, Qiu Y, Lv L, Zhang Z Cancer Innov. 2024; 3(5):e135.

PMID: 38948899 PMC: 11212276. DOI: 10.1002/cai2.135.


References
1.
Ladenstein R, Lambert B, Potschger U, Castellani M, Lewington V, Bar-Sever Z . Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2017; 45(2):292-305. PMC: 5747549. DOI: 10.1007/s00259-017-3829-7. View

2.
Schleiermacher G, Janoueix-Lerosey I, Delattre O . Recent insights into the biology of neuroblastoma. Int J Cancer. 2014; 135(10):2249-61. DOI: 10.1002/ijc.29077. View

3.
Bitencourt A, Gibbs P, Rossi Saccarelli C, Daimiel I, Gullo R, Fox M . MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer. EBioMedicine. 2020; 61:103042. PMC: 7648120. DOI: 10.1016/j.ebiom.2020.103042. View

4.
Loh A, Angelina C, Wong M, Tan S, Sukhatme S, Yeo T . Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse. Front Oncol. 2022; 12:939460. PMC: 9513238. DOI: 10.3389/fonc.2022.939460. View

5.
Nour-Eldin N, Abdelmonem O, Tawfik A, Naguib N, Klingebiel T, Rolle U . Pediatric primary and metastatic neuroblastoma: MRI findings: pictorial review. Magn Reson Imaging. 2012; 30(7):893-906. DOI: 10.1016/j.mri.2012.02.028. View